Enzyme-Linked DNA Displacement (ELIDIS) Assay as an innovative immunoassay platform
Develop and validate a novel immunoassay, ELIDIS, as a portable, efficient alternative to ELISA for biotech and biopharma applications, enhancing accessibility and ease of use.
Projectdetails
Since its introduction more than 50 years ago, ELISA (Enzyme-Linked Immunosorbent Assay) remains one of the most widely used technologies for research, drug discovery, and diagnosis.
Introduction
The reasons for this extraordinary longevity are manifold: ELISA combines the high specificity of antibody-antigen interactions with the high sensitivity of enzyme amplification. However, ELISA also has disadvantages: multiple washing steps and reagents are required, and a specialized instrument is needed, which is not always available in all laboratories. An innovative immunoassay technology that can overcome the limitations of ELISA while retaining all of its best features would therefore represent a turning point in the global immunoassay market (> $35 billion in 2023).
Development of ELIDIS
Under the ERC Consolidator Grant PRO-TOOLKITS, we have developed a novel immunoassay, which we have named Enzyme-Linked DNA Displacement (ELIDIS). This technology has all the characteristics to meet the need for an alternative to ELISA.
Overview of ELIDIS
In short, ELIDIS involves two steps and is based on the use of enzyme-conjugated DNA strands and disposable electrodes. ELIDIS retains the advantageous properties of ELISA (high sensitivity and specificity) but, unlike ELISA, is easier to perform. It does not require enzyme-labeled antibodies and, more importantly, can be performed using portable electronic devices such as a laptop or smartphone without the need for additional instruments.
Project Goals
With these considerations in mind, in this PoC project we will validate the ELIDIS assay as a candidate to replace ELISA in any biotech and biopharma laboratory. To achieve this goal, we will:
- Validate the ELIDIS assay for the detection of two model targets (Trastuzumab and EGFR).
- Develop two prototype kits using disposable sensor arrays and a portable device (or an app/software).
- Create a “manufacturing plan” for assay production.
- Develop an IP strategy for patent filing/maintenance.
- Create a plan for business/commercialization.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-11-2024 |
Einddatum | 30-4-2026 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- ISTITUTO NAZIONALE DI BIOSTRUTTURE E BIOSISTEMIpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORINGThe project aims to evaluate the commercial potential of a novel DNA-based platform for rapid and cost-effective detection of bispecific antibodies to monitor immunotherapy efficacy. | ERC Proof of... | € 150.000 | 2022 | Details |
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnosticsPRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries. | ERC Proof of... | € 150.000 | 2023 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
CRISPR Point-of-Care DiagnosticsDeveloping a streamlined, one-step CRISPR-Cas diagnostic tool for rapid and accurate detection of COPD pathogens, enhancing point-of-care diagnostics and commercialization potential. | ERC Proof of... | € 150.000 | 2022 | Details |
High-throughput combinatory drugs testing on in vitro 3D cells model platformThe project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer. | ERC Proof of... | € 150.000 | 2023 | Details |
ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORING
The project aims to evaluate the commercial potential of a novel DNA-based platform for rapid and cost-effective detection of bispecific antibodies to monitor immunotherapy efficacy.
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics
PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.
CRISPR Point-of-Care Diagnostics
Developing a streamlined, one-step CRISPR-Cas diagnostic tool for rapid and accurate detection of COPD pathogens, enhancing point-of-care diagnostics and commercialization potential.
High-throughput combinatory drugs testing on in vitro 3D cells model platform
The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritizationValo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates. | EIC Transition | € 2.226.280 | 2023 | Details |
ECL-based Infectious Pathogen (bio)SEnsorECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics. | EIC Pathfinder | € 2.683.996 | 2022 | Details |
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to LabBiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening. | EIC Transition | € 2.500.000 | 2022 | Details |
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnosticsScope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare. | EIC Transition | € 2.498.125 | 2024 | Details |
IncoTIMEHet project richt zich op het verbeteren van het coatingsproces voor microfluïdische cartridges, met als doel een schaalbaar en economisch productieprotocol voor Point of Care diagnostische testen te ontwikkelen. | Mkb-innovati... | € 180.950 | 2023 | Details |
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization
Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.
ECL-based Infectious Pathogen (bio)SEnsor
ECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics.
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to Lab
BiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening.
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics
Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.
IncoTIME
Het project richt zich op het verbeteren van het coatingsproces voor microfluïdische cartridges, met als doel een schaalbaar en economisch productieprotocol voor Point of Care diagnostische testen te ontwikkelen.